Skip to content

Determination of the median effective dose (ED50) of intrathecal dexmedetomidine as an adjuvant to ropivacaine during spinal anesthesia for cesarean section

Determination of the median effective dose (ED50) of intrathecal dexmedetomidine as an adjuvant to ropivacaine during spinal anesthesia for cesarean section

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058367
Enrollment
Unknown
Registered
2022-04-07
Start date
2022-04-07
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section under spinal anesthesia

Interventions

group 1:ropivacaine 8 mg +dexmedetomidine
group 2:ropivacaine 10 mg +dexmedetomidine

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Elective cesarean section in healthy parturient.

Exclusion criteria

Exclusion criteria: 1.Patients with respiratory, cardiovascular, renal, hepatic, endocrine and neurological diseases.

Design outcomes

Primary

MeasureTime frame
The effective or ineffective of the intrathecal block;

Secondary

MeasureTime frame
Sensory and Motor block leve;Visceral traction response;Abdominal muscle relaxation;Shivering scores and sedation scores;Satisfaction;Pain scores;Side effects;Time to first urination after the extubation of the catheters;The blood gas analysis of the umbilical vein;Apgar scores;BP;HR;

Countries

china

Contacts

Public ContactXiaoFei Mo

Guangzhou Women and Children's Medical Center

13560336485@163.com+86 13560336485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026